Oncolytic Adenovirus Harboring Interleukin-24 Improves Chemotherapy for Advanced Prostate Cancer

Mao, Lijun; Ding, Meng; Xu, Kai; Yu, Haiyuan; Yang, Chunhua

doi:10.7150/jca.26437

Cited by 16 publications

(12 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An oncolytic adenovirus coding for GM-CSF resulted in the induction of potent antitumor immunity and significant therapeutic effects in patients with solid tumors resistant to standard treatment [ 128 ]. Analogous examples include engineering OVs to encode interleukins, such as IL-12 or IL24, that function as inflammatory stimuli to promote immunological infiltration of the tumor microenvironment, which can strengthen efficacy when used in addition to other tumor therapeutics [ 131 , 132 ].…”

Section: Enhancing the Antitumor Effect By Combination Strategies Incmentioning

confidence: 99%

Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy

Zhang

Cheng

2020

Mol Cancer

View full text Add to dashboard Cite

As a promising therapeutic strategy, oncolytic virotherapy has shown potent anticancer efficacy in numerous pre-clinical and clinical trials. Oncolytic viruses have the capacity for conditional-replication within carcinoma cells leading to cell death via multiple mechanisms, including direct lysis of neoplasms, induction of immunogenic cell death, and elicitation of innate and adaptive immunity. In addition, these viruses can be engineered to express cytokines or chemokines to alter tumor microenvironments. Combination of oncolytic virotherapy with other antitumor therapeutic modalities, such as chemotherapy and radiation therapy as well as cancer immunotherapy can be used to target a wider range of tumors and promote therapeutic efficacy. In this review, we outline the basic biological characteristics of oncolytic viruses and the underlying mechanisms that support their use as promising antitumor drugs. We also describe the enhanced efficacy attributed to virotherapy combined with other drugs for the treatment of cancer.

show abstract

Section: Enhancing the Antitumor Effect By Combination Strategies Incmentioning

confidence: 99%

Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy

Zhang

Cheng

2020

Mol Cancer

View full text Add to dashboard Cite

show abstract

“…Current preclinical and clinical data support the notion that the therapeutic efficacy of oncolytic virus is very limited as monotherapy and joint therapy may perform better than each drug used alone. Numerous preclinical studies are ongoing which can be divided into different categories, (1) oncolytic virus expressing immune checkpoint inhibitor [72,73], (2) expressing immunestimulating cytokines [74,75], (3) combination with small molecules [71,76], (4) combination with radiotherapy [77].…”

Section: Oncolytic Virus (Ovs)mentioning

confidence: 99%

An overview of development in gene therapeutics in China

Wang

Cai

2020

Gene Ther

View full text Add to dashboard Cite

After setbacks related to serious adverse events 20 years ago, gene therapy is now coming back to the central stage worldwide. In the past few years, gene therapy has shown astonishing efficacy against genetic diseases and cancers. In history, China carried out the world's second gene therapy clinical trial in 1991 for hemophilia B and approved the world's first gene therapy product-Gendicine-in 2003. In recent years, numerous efforts have been made on gene editing. Here, we reviewed the past of gene therapy in China and highlighted recent advances. We also discussed the regulations and future perspectives of gene therapy in China.

show abstract

“…Ad5-yCD/mutKSR39rep-hIL12 (Table 1) is an oncolytic adenovirus combining IL-12 and yeast cytosine deaminase (yCD) which is in a Phase-I clinical trial in pancreatic cancer (NCT03281382). OAds have also been armed with: IL-15 [125,126], IL-21 [127], or IL-24 [128][129][130][131][132][133].…”

Section: Oncos-102mentioning

confidence: 99%

Effect of Transgene Location, Transcriptional Control Elements and Transgene Features in Armed Oncolytic Adenoviruses

Farrera-Sal

Fillat

Alemany

2020

Cancers

View full text Add to dashboard Cite

Clinical results with oncolytic adenoviruses (OAds) used as antitumor monotherapies show limited efficacy. To increase OAd potency, transgenes have been inserted into their genome, a strategy known as "arming OAds". Here, we review different parameters that affect the outcome of armed OAds. Recombinant adenovirus used in gene therapy and vaccination have been the basis for the design of armed OAds. Hence, early region 1 (E1) and early region 3 (E3) have been the most commonly used transgene insertion sites, along with partially or complete E3 deletions. Besides transgene location and orientation, transcriptional control elements, transgene function, either virocentric or immunocentric, and even the codons encoding it, greatly impact on transgene levels and virus fitness.

show abstract

Oncolytic Adenovirus Harboring Interleukin-24 Improves Chemotherapy for Advanced Prostate Cancer

Cited by 16 publications

References 26 publications

Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy

Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy

An overview of development in gene therapeutics in China

Effect of Transgene Location, Transcriptional Control Elements and Transgene Features in Armed Oncolytic Adenoviruses

Contact Info

Product

Resources

About